| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Fibroblast growth factor receptor substrate 2; FGFR substrate 2; FGFR-signaling adaptor SNT; Suc1-associated neurotrophic factor target 1; SNT-1 |
| Entrez GeneID | 10818 |
| WB Predicted band size | Calculated MW: 57 kDa; Observed MW: 57 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human FRS2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于FRS2抗体的模拟参考文献示例(请注意，这些为虚构示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*"FRS2 Antibody Validation in FGFR Signaling Pathways"*
**作者**：Smith A, et al.
**摘要**：本研究验证了一种针对FRS2蛋白的高特异性单克隆抗体，通过Western blot和免疫荧光技术证实其在检测内源性FRS2表达及磷酸化状态中的可靠性。结果显示该抗体适用于研究FRS2在成纤维细胞生长因子受体(FGFR)信号传导中的动态调控。
2. **文献名称**：*"Role of FRS2 in Breast Cancer Metastasis: Insights from Antibody-Based Inhibition"*
**作者**：Chen L, et al.
**摘要**：利用FRS2抗体阻断其功能，研究者发现FRS2通过调控ERK/MAPK通路促进乳腺癌细胞迁移。该抗体被用于免疫共沉淀实验，揭示FRS2与下游效应蛋白的相互作用，为靶向治疗提供依据。
3. **文献名称**：*"Development of a Phospho-Specific FRS2 Antibody for Tyrosine Phosphorylation Studies"*
**作者**：Yamamoto K, et al.
**摘要**：本文报道了一种新型磷酸化特异性FRS2抗体的开发，可特异性识别Tyr436位点的磷酸化修饰。该抗体成功应用于检测生长因子刺激后FRS2的激活状态，并用于小鼠胚胎发育模型中信号通路的动态分析。
4. **文献名称**：*"Comparative Analysis of Commercial FRS2 Antibodies in Neuronal Differentiation Models"*
**作者**：Garcia R, et al.
**摘要**：研究对比了三种市售FRS2抗体的特异性和灵敏度，发现其中两种适用于免疫组化检测神经元分化过程中FRS2的亚细胞定位，为神经发育研究中的抗体选择提供了实用指南。
---
**建议**：如需真实文献，可通过PubMed、Google Scholar等平台检索关键词“FRS2 antibody”或“FRS2 + [研究领域]”，筛选近年高被引论文。部分真实相关研究可能涉及FRS2在癌症、发育或信号转导中的功能机制及抗体应用。
The FRS2 (Fibroblast Growth Factor Receptor Substrate 2) antibody is a crucial tool for studying FRS2. a key adaptor protein in fibroblast growth factor receptor (FGFR) signaling pathways. FRS2 is recruited to activated FGFRs via its N-terminal phosphotyrosine-binding (PTB) domain, facilitating downstream signal transduction. It undergoes tyrosine phosphorylation upon FGFR activation, creating docking sites for effector proteins like Grb2 and SOS1. which activate RAS-MAPK and PI3K-AKT pathways. These pathways regulate essential cellular processes, including proliferation, differentiation, survival, and tissue development. Dysregulation of FRS2 is implicated in cancers, developmental disorders, and metabolic diseases.
The FRS2 antibody enables researchers to detect and quantify FRS2 expression, phosphorylation status, and interactions in techniques such as Western blotting, immunoprecipitation, and immunofluorescence. It is particularly valuable in cancer research, where aberrant FGFR-FRS2 signaling drives tumor progression and therapy resistance. By studying FRS2 dynamics, scientists gain insights into disease mechanisms and potential therapeutic targets. Commercially available FRS2 antibodies are typically validated for specificity and sensitivity across human, mouse, and rat models, supporting translational and preclinical studies. Understanding FRS2's role through antibody-based assays continues to advance precision medicine and drug development in FGFR-related pathologies.
×
